EmblemHealth denied immediate appeal in US antitrust case over Soliris
MLex Summary: EmblemHealth failed to convince a US federal judge to allow it to immediately appeal the dismissal of its antitrust claims against Alexion Pharmaceuticals over the drug Soliris. Statement follows in...To view the full article, register now.
Already a subscriber? Click here to view full article